Although immune checkpoint inhibitors (cytotoxic T-lymphocyte-associated antigen-4 [CTLA-4] inhibitors, programmed death-1 [PD-1] inhibitors, and programmed death-ligand-1 [PD-L1] inhibitors) have been increasingly used in recent years to treat various malignancies (melanoma, pancreatic cancer, and non-small cell lung cancer), pituitary inflammation caused by immune checkpoint inhibitors has been reported [71, 72]. The gene discussed is CTLA4; the disease is melanoma.